| Drug Name |
Ramelteon |
| Drug ID |
BADD_D01908 |
| Description |
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. |
| Indications and Usage |
For the treatment of insomnia characterized by difficulty with sleep onset. |
| Marketing Status |
approved; investigational |
| ATC Code |
N05CH02 |
| DrugBank ID |
DB00980
|
| KEGG ID |
D02689
|
| MeSH ID |
C495910
|
| PubChem ID |
208902
|
| TTD Drug ID |
D0U0KW
|
| NDC Product Code |
0591-2191; 59651-505; 63629-8531; 70010-028; 71205-918; 72189-369; 63415-0150; 50268-708; 42571-375; 43598-741; 52817-235; 64764-805; 72189-484; 60687-692; 70771-1495; 42413-0180; 73435-003; 50436-3980; 71335-2186; 14501-0030; 76397-021; 76397-032; 55700-874; 63629-8264; 59651-469; 66332-0014; 72189-153; 0832-1250; 42291-776; 70710-1344; 80425-0203; 80425-0343; 70700-272; 72319-005; 71335-1853; 58159-050 |
| UNII |
901AS54I69
|
| Synonyms |
ramelteon | (S)-N-(2-(1,6,7,8-tetrahydro-2H-indeno-(5,4)furan-8-yl)ethyl)propionamide | TAK-375 | Rozerem |
